Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gemcitabine and UFT plus oral calcium folinate: Phase I study
Autore:
Philip, PA; Ibrahim, D; Zalupski, M; Arlauskas, P; Shields, A;
Indirizzi:
Wayne State Univ, Barbara Ann Karmanos Canc Inst, Div Hematol & Oncol, Detroit, MI 48201 USA Wayne State Univ Detroit MI USA 48201 atol & Oncol, Detroit, MI 48201 USA
Titolo Testata:
ONCOLOGY-NEW YORK
fascicolo: 7, volume: 13, anno: 1999, supplemento:, 3
pagine: 116 - 119
SICI:
0890-9091(199907)13:7<116:GAUPOC>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
7
Recensione:
Indirizzi per estratti:
Indirizzo: Philip, PA Wayne State Univ, Barbara Ann Karmanos Canc Inst, Div Hematol &Oncol, Detroit, MI 48201 USA Wayne State Univ Detroit MI USA 48201 l, Detroit, MI 48201 USA
Citazione:
P.A. Philip et al., "Gemcitabine and UFT plus oral calcium folinate: Phase I study", ONCOLOGY-NY, 13(7), 1999, pp. 116-119

Abstract

Gemcitabins (Gemzar) is a nucleoside analog increasingly used in the treatment of a variety of solid tumors. DNA synthesis is inhibited by gemcitabine by masked chain termination and via inhibition of ribonucleotide reductase. Synergy may exist between gemcitabine and other antimetabolites, including 5-fluorouracil. The varying patterns of dose-limiting toxicities to gemcitabine and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral calciumfolinate (Orzel) permit their use in combination. The primary aint of thisphase I study is to determine the maximum tolerated doses of gemcitabine and UFT plus oral calcium folinate irt patients with a variety of solid tumors. Only eight patients have been recruited to date,,vith myelosuppression being the main toxicity observed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/07/20 alle ore 07:22:20